The role of uric acid in the development of cognitive disorders in patients with metabolic syndrome
https://doi.org/10.18705/2311-4495-2015-0-6-64-69
Abstract
Objective. To evaluate the role of increased level of uric acid in the development of cognitive disorders in patients with metabolic syndrome (MS). Design and methods. Were included in the study and examined using anthropometry, biochemical blood analysis of 84 patients with MS (n = 44 with cognitive impairments and n = 40 without cognitive deficits). Cognitive function was assessed by applying neuropsychological scales. Quantitative assessment of cognitive functions was determined by the method of cognitive evoked potential with EMG/EP Nicolet Viking Select. Results. Revealed increased levels of uric acid (0,54 ± 0,32 and 0,36 ± 0,15 mmol/l, respectively, p < 0.01) in the group of patients with MS and cognitive disorders compared with the group without cognitive disorders. There was correlation between the level of uric acid and parameters of neurodynamic testing. In patients with increased uric acid level was registered the increase of the duration of the latent period of cognitive evoked potential (r = 0,42, p = 0,002). Conclusion. The obtained results give reason to assume that one of the mechanisms of development of cognitive impairment in patients with MS is to increase the level of uric acid in serum.
About the Authors
I. B. Zueva
Federal Almazov North-West medical research centre named after V. A. Almazov
Russian Federation
Russian Federation
R. V. Golikova
First St. Petersburg Pavlov State Medical University
Russian Federation
Russian Federation
D. S. Krivonosov
Federal Almazov North-West medical research centre named after V. A. Almazov
Russian Federation
Russian Federation
E. L. Urumova
Federal Almazov North-West medical research centre named after V. A. Almazov
Russian Federation
Russian Federation
G. G. Baratashvili
Federal Almazov North-West medical research centre named after V. A. Almazov
Russian Federation
Russian Federation
References
1. Bos M.J. Uric acid is a risk factor for myocardial infarction and stroke; The Rotterdam Study. Stroke. 2006; 37: 1503.
2. Zhu X., Raina A.K., Perry G. et al. Alzheimer>s disease: the two-hit hypothesis. Lancet Neurol. 2004;3: 219-26.
3. Johnson R. J., Kang D. H., Feig D. et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003; 41: 1183-90.
4. Kim T.S., Pae C.U., Yoon S.J. et al. Decreased plasma antioxidants in patients with Alzheimer>s disease. Int J Geriatr Psychiatry. 2006; 21: 344-8.
5. Schretlen D.J., Inscore A.B., Vannorsdall T.D. et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology. 2007; 69: 1418-1423.
6. Irizarry M.C., Reman R., Schwarzschild M.A. et al. Plasma urate and progression of mild cognitive impairment. Neurodegener Dis.- Dec 2009; 6(1-2): 23-28.
7. Vernoolj M.W., Ikram M.A., Vrooman H.A. et al. White matter microstructural integrity and cognitive function in a general elderly population. Arch Gen Psychiatry. 2009 May; 66 (5): 545-53.
8. Ford E.S., Li C., Cook S., Choi H.K. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation. 2007; 115 (19): 2526-2532.
9. Pacifico L., Cantisani V., Anania C., et al. Serum uric acid and its association with metabolic syndrome and carotid atherosclerosis in obese children. European Journal of Endocrinology. 2009; 160 (1): 45-52.
10. Kramer C.K., von Mühlen D., Jassal S.K., Barrett-Connor E. Serum uric acid levels improve prediction of incident type 2 diabetes in individuals with impaired fasting glucose: the Rancho Bernardo Study. Diabetes Care. 2009; 32 (7): 1272-1273.
11. Lee Y.J., Lee J.H., Shin Y.H. et al. Gender difference and determinants of C-reactive protein level in Korean adults. Clinical Chemistry and Laboratory Medicine.- 2009; 47 (7): 863-869.
12. Kang D-H., Park S-K., Lee I-K., Johnson R.J. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. Journal of the American Society of Nephrology. 2005;16 (12): 3553-3562.
13. Sowers J.R., Whaley-Connell A., Hayden M.R. The role of overweight and obesity in the cardiorenal syndrome. Cardiorenal Med. 2011; 1: 5-12.
14. Sowers J.R. Diabetes mellitus and vascular disease. Hypertension. 2013; 61: 943-947.
15. Fazekas F., Schmidt R., Scheltens P. Pathophysiologic mechanisms in the development of age-related white matter changes of the brain. Dement Geriatr Cogn Disord.- 1998; 9 (suppl 1): 2-5.
Review
For citations:
Zueva I.B., Golikova R.V., Krivonosov D.S., Urumova E.L., Baratashvili G.G. The role of uric acid in the development of cognitive disorders in patients with metabolic syndrome. Translational Medicine. 2015;(6):64-69. (In Russ.) https://doi.org/10.18705/2311-4495-2015-0-6-64-69
Views:
831
Email this article 